1001908-89-9

1001908-89-9 structure

Name: SRT 2183
Chemical Name: srt2183
CAS Number: 1001908-89-9
Molecular Formula: C₂₇H₂₄N₄O₂S
Molecular Weight: 468.57
Catalog: Signaling Pathways Cell Cycle/DNA Damage Sirtuin
Create Date: 2018-02-22 08:02:19
Modify Date: 2024-01-12 07:58:22
SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC1.5 value of 0.36 μM[1]. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels[2].

Name	srt2183

Description	SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC1.5 value of 0.36 μM[1]. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels[2].
Related Catalog	Signaling Pathways >> Epigenetics >> Sirtuin Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Sirtuin
Target	SIRT1:0.36 μM (EC1.5)
In Vitro	SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner[2]. SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels[2]. SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival[3]. Cell Proliferation Assay[2] Cell Line: Reh cells, Nalm-6 cells (pre-B acute lymphoblastic leukemia (ALL) cell lines) Concentration: 1 μM, 5 μM, 10 μM Incubation Time: 24 hours, 48 hours, 72 hours Result: Inhibited the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. The IC50 (median inhibition concentration) values for SRT 2183-mediated inhibition of proliferation at 48 h are approximately 8.7 μM for Reh cells and approximately 3.2 μM for Nalm-6 cells. Western Blot Analysis[2] Cell Line: Reh cells, Ly3 cells Concentration: 5μM and 10μM (Reh cells); 10μM (Ly3 cells) Incubation Time: 24 hours Result: Induced accumulation of phospho-H2A.X in Reh as well as in Ly3 cells.
References	[1]. Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712–716. [2]. Scuto A, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May; 4(5): e635. [3]. Gurt I, et al. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.

Molecular Formula	C₂₇H₂₄N₄O₂S
Molecular Weight	468.57
Exact Mass	468.16200
PSA	98.11000
LogP	5.04580
Storage condition	-20℃

1001908-89-9	925434-55-5
2060259-60-9	1093403-33-8
925432-73-1	2468639-77-0
1001645-58-4	1204707-71-0
925889-73-2	1092960-96-7